This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Benchmarks provide objective yardsticks to assess results, set expectations, and keep portfolios aligned with objectives.
20,321 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Trillions moving to heirs may redefine how leaders rise in corporate America. This report explores what the shift cou...
As software shares pull back in 2026, you don’t have to chase chaos. This article identifies one software stock actua...
A high dividend can spark doubt. This article breaks down pfizer's 6.5% dividend yield, what it signals about the bus...
A corporate treasury model pivots back to Bitcoin buying after a pause, adopting a clear buy-for-sell rule. This appr...
As market nerves flare, investors look for a safe-haven that’s practical to own. This Vanguard could be a better ball...
A routine ethics filing has become a focal point for investors and policymakers. This deep dive explains what the qua...
A large fund sold about $17 million in ZoomInfo shares while the company posted slim revenue growth. This article bre...
A high-stakes portfolio shuffle by a famed activist investor grabbed headlines. This piece breaks down what happened,...
Investors wonder if AMD can reach a trillion-dollar milestone in the fast-changing chip landscape. This article break...
Amazon continues to trim staff in a bid to reset costs and refocus on core growth areas. This article breaks down wha...
Archer Aviation stock popped last month as investors weighed milestones in eVTOL development, defense partnerships, a...